Axsome Therapeutics

AXSM

Market cap $9.42B

Axsome Therapeutics has performed well since its IPO. The company's current lineup and pipeline could drive growth for a while.

NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the first quarter of 2026 on Monday, May 4, 2026, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update.

Summit Therapeutics shares could drop later this year if it doesn't earn approval for its leading candidate. Madrigal Pharmaceuticals and Axsome Therapeutics could move in the opposite direction.

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?

Superstring Capital Management purchased 37,433 shares of Axsome Therapeutics in the fourth quarter. The quarter-end position value was $6.84 million, representing a new holding in Axsome Therapeutics.

Axsome's lead product, Auvelity, sales jumped 74% to $507M in 2025, fueling growth while other drugs added momentum.

Axsome Therapeutics, Inc. (AXSM) Presents at The Citizens Life Sciences Conference 2026 Transcript

Axsome Therapeutics, Inc. (AXSM) Presents at Leerink Global Healthcare Conference 2026 Transcript

Axsome Therapeutics has an exciting late-stage pipeline. Madrigal Pharmaceuticals is looking to dominate a large market with significant unmet needs.

32,410 shares were exercised and sold for a total transaction value of ~$6.0 million on February 2, 2026. After this transaction, Tabuteau directly held 7,229 shares and indirectly held 7,344,500 shares.